GMMA as a ‘plug and play’ technology to tackle infectious disease to improve global health: context and perspectives for the future

References

• Gnopo YMD, Watkins HC, Stevenson TC, et al. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev. 2017;114:132–142.
   PubMed Web of Science ®Google Scholar
• Jan AT. Outer Membrane Vesicles (OMVs) of gram-negative bacteria: a perspective update. Front Microbiol. 2017;8:1053.
   PubMed Web of Science ®Google Scholar
• van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. Biotechnol J. 2015;10(11):1689–1706.
   PubMed Web of Science ®Google Scholar
• Chatterjee SN, Das J. Electron microscopic observations on the excretion of cell-wall material by Vibrio cholerae. J Gen Microbiol. 1967;49(1):1–11.
   PubMedGoogle Scholar
• McBroom AJ, et al. Outer membrane vesicle production by Escherichia coli is independent of membrane instability. J Bacteriol. 2006;188(15):5385–5392.
   PubMed Web of Science ®Google Scholar
• Toyofuku M, Nomura N, Eberl L. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17(1):13–24.
   PubMed Web of Science ®Google Scholar
• Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev. 2010;74(1):81–94.
   PubMed Web of Science ®Google Scholar
• Schooling SR, Beveridge TJ. Membrane vesicles: an overlooked component of the matrices of biofilms. J Bacteriol. 2006;188(16):5945–5957.
   PubMed Web of Science ®Google Scholar
• Rumbo C, et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(7):3084–3090.
   PubMed Web of Science ®Google Scholar
• Kadurugamuwa JL, Beveridge TJ. Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol. 1995;177(14):3998–4008.
   PubMed Web of Science ®Google Scholar
• Li M, Zhou H, Yang C, et al. Bacterial outer membrane vesicles as a platform for biomedical applications: an update. J Control Release. 2020;323:253–268.
   PubMed Web of Science ®Google Scholar
• Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol. 2020;50:101433.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291–295.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384.
   PubMed Web of Science ®Google Scholar
• Mancini F, et al. OMV vaccines and the role of TLR Agonists in immune response. Int J Mol Sci. 2020;21(12).
   Web of Science ®Google Scholar
• MacLennan CA. Vaccines for low-income countries. Semin Immunol. 2013;25(2):114–123.
   PubMed Web of Science ®Google Scholar
• Tan K, Li R, Huang X, et al. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants. Front Microbiol. 2018;9:783.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–796.
   PubMed Web of Science ®Google Scholar
• Benne N, van Duijn J, Kuiper J, et al. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines. J Control Release. 2016;234:124–134.
   PubMed Web of Science ®Google Scholar
• Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest. 2016;126(3):799–808.
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–12.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Masignani V, et al. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–1121.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Pizza M, Masignani V, et al. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines. 2017;16(5):433–451.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30.
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816–1820.
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97.
   PubMed Web of Science ®Google Scholar
• Nieves W, Petersen H, Judy BM, et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol. 2014;21(5):747–754.
   PubMed Web of Science ®Google Scholar
• Liu Q, et al. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge. Sci Rep. 2016;6(1):34776.
   PubMedGoogle Scholar
• Camacho AI, de Souza J, Sánchez-Gómez S, et al. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine. 2011;29(46):8222–8229.
   PubMed Web of Science ®Google Scholar
• Mitra S, Chakrabarti MK, Koley H. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis. Vaccine. 2013;31(31):3163–3173.
   PubMed Web of Science ®Google Scholar
• Roier S, Leitner DR, Iwashkiw J, et al. Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice. PLoS One. 2012;7(8):e42664.
   PubMed Web of Science ®Google Scholar
• Bishop AL, Schild S, Patimalla B, et al. Mucosal immunization with vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun. 2010;78(10):4402–4420.
   PubMed Web of Science ®Google Scholar
• Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun. 2008;76(10):4554–4563.
   PubMed Web of Science ®Google Scholar
• Sedaghat M, Siadat SD, Mirabzadeh E, et al. Evaluation of antibody responses to outer membrane vesicles (OMVs) and killed whole cell of vibrio cholerae O1 El Tor in immunized mice. Iran J Microbiol. 2019;11(3):212–219.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang F, Zou J, et al. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice. Vaccine. 2018;36(8):1047–1054.
   PubMed Web of Science ®Google Scholar
• Zhao K, Deng X, He C, et al. Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the Toll-like receptor 4 signaling pathway. Infect Immun. 2013;81(12):4509–4518.
   PubMed Web of Science ®Google Scholar
• Lee WH, Choi H-I, Hong S-W, et al. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp Mol Med. 2015;47(9):e183.
   PubMedGoogle Scholar
• Wu G, Ji H, Guo X, et al. Nanoparticle reinforced bacterial outer-membrane vesicles effectively prevent fatal infection of carbapenem-resistant Klebsiella pneumoniae. Nanomedicine. 2020;24:102148.
   PubMed Web of Science ®Google Scholar
• Bottero D, Gaillard ME, Zurita E, et al. Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine. 2016;34(28):3303–3309.
   PubMed Web of Science ®Google Scholar
• Gaillard ME, Bottero D, Errea A, et al. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine. 2014;32(8):931–937.
   PubMed Web of Science ®Google Scholar
• Raeven RH, et al. Immunoproteomic profiling of bordetella pertussis outer membrane vesicle vaccine reveals broad and balanced humoral immunogenicity. J Proteome Res. 2015;14(7):2929–2942.
   PubMed Web of Science ®Google Scholar
• Pierson T, et al. Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine. J Proteome Res. 2011;10(3):954–967.
   PubMed Web of Science ®Google Scholar
• Ferrari G, et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics. 2006;6(6):1856–1866.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd B, Mommen GPM, Pennings JLA, et al. Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines. J Proteome Res. 2013;12(4):1898–1908.
   PubMed Web of Science ®Google Scholar
• Rosenqvist E, et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand. 1998;92:323–333.
   PubMedGoogle Scholar
• Shah RR, Hassett KJ, Brito LA. Overview of vaccine adjuvants: introduction, history, and current status. Methods Mol Biol. 2017;1494:1–13.
   PubMedGoogle Scholar
• Colaprico A, Senesi S, Ferlicca F, et al. Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. Vaccine. 2020;38(19):3600–3609.
   PubMed Web of Science ®Google Scholar
• Kis Z, Shattock R, Shah N, et al. Emerging technologies for low-cost, rapid vaccine manufacture. Biotechnol J. 2019;14(1):e1800376.
   PubMed Web of Science ®Google Scholar
• Berlanda Scorza F, Colucci AM, Maggiore L, et al. High yield production process for Shigella outer membrane particles. PLoS One. 2012;7(6):e35616.
   PubMed Web of Science ®Google Scholar
• Gerke C, Colucci AM, Giannelli C, et al. Production of a Shigella sonnei vaccine based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. PLoS One. 2015;10(8):e0134478.
   PubMed Web of Science ®Google Scholar
• Bernadac A, Gavioli M, Lazzaroni J-C, et al. Escherichia coli tol-pal mutants form outer membrane vesicles. J Bacteriol. 1998;180(18):4872–4878.
   PubMed Web of Science ®Google Scholar
• Kulp AJ, Sun B, Ai T, et al. Genome-wide assessment of outer membrane vesicle production in Escherichia coli. PLoS One. 2015;10(9):e0139200.
   PubMed Web of Science ®Google Scholar
• Mitra S, Sinha R, Mitobe J, et al. Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain. Vaccine. 2016;34(15):1839–1846.
   PubMed Web of Science ®Google Scholar
• Roier S, Zingl FG, Cakar F, et al. A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat Commun. 2016;7(1):10515.
   PubMedGoogle Scholar
• Turner L, Praszkier J, Hutton ML, et al. Increased outer membrane vesicle formation in a helicobacter pylori tolB mutant. Helicobacter. 2015;20(4):269–283.
   PubMed Web of Science ®Google Scholar
• Gerritzen MJH, Salverda MLM, Martens DE, et al. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification. Vaccine. 2019;37(47):6978–6986.
   PubMed Web of Science ®Google Scholar
• Gerritzen MJH, Stangowez L, van de Waterbeemd B, et al. Continuous production of Neisseria meningitidis outer membrane vesicles. Appl Microbiol Biotechnol. 2019;103(23–24):9401–9410.
   PubMed Web of Science ®Google Scholar
• Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191–1195.
   PubMed Web of Science ®Google Scholar
• Schromm AB, Brandenburg K, Loppnow H, et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem. 2000;267(7):2008–2013.
   PubMedGoogle Scholar
• Rossi O, Caboni M, Negrea A, et al. Toll-like receptor activation by generalized modules for membrane antigens from lipid a mutants of Salmonella enterica serovars typhimurium and enteritidis. Clin Vaccine Immunol. 2016;23(4):304–314.
   PubMed Web of Science ®Google Scholar
• Rossi O, Pesce I, Giannelli C, et al. Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants. J Biol Chem. 2014;289(36):24922–24935.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Black S, Bloom DE. Vaccines and global health: in search of a sustainable model for vaccine development and delivery. Sci Transl Med. 2019;11(497).
   PubMed Web of Science ®Google Scholar
• WHO. 2009. State of the world’s vaccines and immunization. 3rd ed.
   Google Scholar
• WHO, Global vaccine action plan 2011-2020. 2013.
   Google Scholar
• WHO. Weekly epidemiological record. WHO position papers; 2004.
   Google Scholar
• Hosangadi D, Smith PG, Kaslow DC, et al. WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: meeting report. Vaccine. 2019;37(50):7381–7390.
   PubMed Web of Science ®Google Scholar
• Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet. 2016;388(10051):1291–1301.
   PubMed Web of Science ®Google Scholar
• Balasubramanian R, Im J, Lee J-S, et al. The global burden and epidemiology of invasive non-typhoidal Salmonella infections. Hum Vaccin Immunother. 2019;15(6):1421–1426.
   PubMed Web of Science ®Google Scholar
• Bekker LG, Tatoud R, Dabis F, et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020;395(10221):384–388.
   PubMed Web of Science ®Google Scholar
• Haselbeck AH, Panzner U, Im J, et al. Current perspectives on invasive nontyphoidal Salmonella disease. Curr Opin Infect Dis. 2017;30(5):498–503.
   PubMed Web of Science ®Google Scholar
• Jones LD, Moody MA, Thompson AB. Innovations in HIV-1 Vaccine Design. Clin Ther. 2020;42(3):499–514.
   PubMed Web of Science ®Google Scholar
• Tennant SM, MacLennan CA, Simon R, et al. Nontyphoidal salmonella disease: current status of vaccine research and development. Vaccine. 2016;34(26):2907–2910.
   PubMed Web of Science ®Google Scholar
• WHO, First malaria vaccine in Africa. 2019.
   Google Scholar
• WHO, Global tuberculosis report 2019. 2019.
   Google Scholar
• Bloom DE, et al. Antimicrobial resistance and the role of vaccines. Proc Natl Acad Sci U S A. 2018;115(51):12868–12871.
   PubMed Web of Science ®Google Scholar
• CDC, Antibiotic resistance threats in the United States, 2019. 2019.
   Google Scholar
• ECDC, Surveillance of antimicrobial resistance in Europe 2018. 2019.
   Google Scholar
• WHO, Global action plan on antimicrobial resistance. 2015.
   Google Scholar
• Micoli F, Bagnoli F, Rappuoli R, et al. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021;19(5):287–302.
   PubMed Web of Science ®Google Scholar
• Launay O, Lewis DJM, Anemona A, et al. Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine. 2017;22:164–172.
   PubMed Web of Science ®Google Scholar
• Launay O, Ndiaye AGW, Conti V, et al. Booster vaccination with GVGH Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European adults: results FROM A PHASE 1 CLINICAL TRIAL. Front Immunol. 2019;10:335.
   PubMed Web of Science ®Google Scholar
• Obiero CW, Ndiaye AGW, Sciré AS, et al. A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a Shigellosis-endemic country. Front Immunol. 2017;8:1884.
   PubMed Web of Science ®Google Scholar
• Micoli F, Rossi O, Conti V, et al. Antibodies elicited by the Shigella sonnei GMMA vaccine in adults trigger complement-mediated serum bactericidal activity: results from a phase 1 dose escalation trial followed by a booster extension. Front Immunol. 2021;12:671325.
   PubMed Web of Science ®Google Scholar
• Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016;34(26):2887–2894.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., et al. Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine. 2021;39:101076.
   PubMedGoogle Scholar
• Micoli F, et al. GMMA is a versatile platform to design effective multivalent combination vaccines. Vaccines (Basel). 2020;8(3.
   Web of Science ®Google Scholar
• Berti F, Micoli F. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. Curr Opin Immunol. 2020;65:42–49.
   PubMed Web of Science ®Google Scholar
• Broker M, Costantino P, DeTora L, et al. Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals. 2011;39(4):195–204.
   PubMed Web of Science ®Google Scholar
• Micoli F, Adamo R, Costantino P. Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends. Molecules. 2018;23(6).
   PubMed Web of Science ®Google Scholar